Pharyngitis
Conditions
Brief summary
The purposes of this study is to demonstrate the analgesic efficacy of flurbiprofen 8.75 mg lozenge compared to its vehicle lozenge and to demonstrate the safety of the flurbiprofen lozenge throughout the course of treating sore throat due to acute pharyngitis.
Interventions
DRUGPlacebo
Participants were instructed to suck one placebo lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
DRUGFlurbiprofen
Participants were instructed to suck one flurbiprofen 8.75 mg lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
Sponsors
Reckitt Benckiser LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The patient has a complaint of sore throat. 2. If the patient is a female of childbearing potential, she has been using effective contraception since the last date of menses and is not breast-feeding or lactating. 3. If the patient is a female of childbearing potential, the patient must have a negative urine pregnancy. 4. The patient has provided written informed consent prior to any study-related procedures.
Exclusion criteria
1. The patient has a history of an upper gastrointestinal ulcer within the past 60 days, is currently experiencing clinically significant upper gastrointestinal complaints, or is currently taking medication regularly (≥ three times in the previous week). 2. The patient has a history of any hepatic disease or renal dysfunction. 3. The patient has a history of chronic analgesic use (≥ three times per week over the prior four weeks). (Patients on low-dose aspirin therapy may be allowed in the study per investigator's clinical decision.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24) | baseline (pre-dose), 24 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-24) | STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID24 was calculated as the sum of the time-weighted pain intensity differences from baseline until 24 hours. The full range was -114609 (complete pain relief within 2 minutes of dosing that lasts 24 hours) to 29191 (maximum pain within 2 minutes lasting 24 hours) using the mean baseline STPIS. Participants with a last recorded time point \<21 hours were considered Not Evaluable. If a participant used rescue medication, all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline | baseline (pre-dose), 2 hours post-dose (every 10 minutes until hour 2) | Participants were asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale at Baseline and 2 hours post dose. Participants were instructed to swallow and Place a line on the scale that best characterizes how difficult it is to swallow now. A mark at 0-mm indicated no difficulty and 100-mm indicated very difficult. Data is reported as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dose. The full range was -9192 (no difficulty swallowing within 10 minutes of dosing that lasts 2 hours) to 2808 (maximum difficulty swallowing within 10 minutes lasting 2 hours) using the baseline DSS value. Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation. |
| Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline | baseline (pre-dose), 24 hours post-dose (every 10 minutes until hour 2, every 30 minutes until hour 6, hourly from 7-24 hours) | Participants were asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale at Baseline and until 24 hours post dose. Participants were instructed to swallow and Place a line on the scale that best characterizes how difficult it is to swallow now. A mark at 0-mm indicated no difficulty and 100-mm indicated very difficult. Data is reported as the sum of the time-weighted pain intensity differences from baseline until 24 hours post dose. The full range was -110304 (no difficulty swallowing within 10 minutes of dosing that lasts 24 hours) to 33696 (maximum difficulty swallowing within 10 minutes lasting 24 hours) using the baseline DSS value. Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation. |
| Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline | baseline (pre-dose), 2 hours post-dose (at 1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, and 2 hours) | The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale at Baseline and at 1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, and 2 hours. The patient was instructed to swallow and Place a line on the scale that best characterizes how swollen your throat feels now. A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 2 hours was -9336 (throat did not feel swollen at all within 1 hour of dosing and lasted 2 hours) to 2664 (maximum swollen throat reported within 1 hour and lasting 2 hours) using the mean baseline SwoTS. |
| Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline | baseline (pre-dose), 24 hours post-dose (1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, 2 hours, 2½ hours, 3 hours, 3½ hours, 4 hours, 4½ hours, 5 hours, 5½ hours, and 6 hours after the first dose, hourly from 7-24 hours) | The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale at Baseline and specified timeframes until 24 hours. The patient was instructed to swallow and Place a line on the scale that best characterizes how swollen your throat feels now. A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 24 hours was -112032 (throat did not feel swollen at all within 1 hour of dosing and lasted 24 hours) to 31968 (maximum swollen throat reported within 1 hour and lasting 24 hours) using the mean baseline SwoTS. |
| Change From Baseline at 24 Hours in the Tonsillo-Pharyngitis Assessment (TPA) Scores in Participants With Baseline TPA Scores >=8 | Baseline (pre-dose), 24 hours post-dose | Tonsillo-Pharyngitis Assessment, or TPA, is an index of seven clinical features of the pain-producing condition itself, pharyngeal inflammation. The clinical features concern temperature, oropharyngeal color, size of tonsils, number of enanthems, largest size of cervical lymph node, number of lymph nodes, and maximum tenderness of lymph nodes. Each variable was rated on a scale of 0-3, with 0 representing the normal value, and 3 representing severe inflammation. The seven values are added together to create the TPA, ranging from 0-21. Negative change values represent improvement of symptoms. |
| Practitioner's Assessment of Pharyngeal Inflammation (P.A.I.N.) Scores at 24 Hours After Initial Dose | 24 hours post-dose | P.A.I.N is a four step scale in which physicians rate the severity of pharyngeal inflammation: No inflammation, mild, moderate and severe inflammation. |
| Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose | 24 hours | Investigators assessed the effectiveness of study medication on the patient's sore throat at 24 hours following initial dose by answering the following question: Considering the patient's response to the study medicine over the past 24 hours, how do you rate the study medicine as a treatment for sore throat? Responses were poor, fair, good, very good or excellent. |
| Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2) | baseline (pre-dose), 2 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2) | STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID2 was calculated as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dosing. The full range was -9405 (complete pain relief within 2 minutes of dosing that lasts 2 hours) to 2395 (maximum pain within 2 minutes lasting 2 hours) using the mean baseline STPIS. If a participant used rescue medication (acetaminophen 650mg was allowed as needed post dose), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (recorded or derived due to rescue) were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose. |
| Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7) | Day 7 | Investigators assessed the effectiveness of study medication on the patient's sore throat at the end of the study by answering the following question: Considering the patient's response to the study medicine over the past 7 days, how do you rate the study medicine as a treatment for sore throat? Responses were poor, fair, good, very good or excellent. |
| Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe | baseline (pre-dose), 24 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-24) | STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. For the subgroup of patients with moderate/severe pharyngeal inflammation at baseline, SPID24 was calculated as the sum of the time weighted pain intensity differences from baseline until 24 hours. Taking inclusion criteria into account, the full range was -116196 (no pain at any post-dose time (0) - average baseline) to 27804 (maximum possible pain (100) - average baseline). Participants with their last recorded time point \<21 hours were considered Not Evaluable. If a participant used rescue medication (acetaminophen 650mg was allowed as needed), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation. |
| Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose | 2 hours | Participants used a 6-category relief scale (no relief to complete relief) to grade the relief of his/her throat pain. The patient was instructed to swallow and: Considering how your throat felt before you took the study medicine, circle the phrase that best describes the relief of your sore throat now. |
| Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | baseline (pre-dose), up to 23 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-23) | Data reported in summary form in Primary Outcome #1 are reported here at each post-dose timepoint until the comparison resulted in a P-value \<=0.05 between the two treatment arms. STPIS was used to measure sore throat pain intensity using a 100-mm visual analog scale completed by participants that measures pain on swallowing (odynophagia). A mark at 0-mm indicates no pain and 100-mm indicates severe pain. The full range of the scale varies by timepoint due to the time weighting sum of SPID. The full scale at 40 minutes post dose was -3188 (complete pain relief within 2 minutes of dosing that lasts 40 minutes) to 812 (maximum pain within 2 minutes lasting 40 minutes) using the mean baseline STPIS. If a participant used rescue medication (acetaminophen 650mg was allowed as needed), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (rec |
| Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement | 2 hours | As part of a protocol amendment, some participants defined a definite improvement level (DIL) relative to their actual pretreatment STPIS on the 100-mm visual analog scale. This was done after completing the 7 day trial. An alternative definition of STPIS time to onset of relief was the time from initial dose to the time the participant reaching DIL for at least 30 minutes. Data were censored if DIL was not achieved by 120 minutes following initial dose. Definite improvement must also occur prior to re-dosing or using rescue medication. |
| Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement Duration of Relief Using Participant-Defined Definite Improvement Levels (DIL) | 6 hours | As part of a protocol amendment, some participants defined a definite improvement level (DIL) relative to their actual pretreatment STPIS on the 100-mm visual analog scale. This was done after completing the 7 day trial. The time of first achieving DIL for 30 minutes within 6 hours (or until rescue or re-dosing) post-dosing will be determined. And the time falling below DIL within 6 hours will be determined. Duration is then defined as the time from first DIL until falling below DIL. Duration was set to zero if the STPIS score does not reach the DIL for at least 30 minutes for STPIS during the 6 hours. |
| Participant Satisfaction Scores 24 Hours After Initial Dose | 24 hours | After 24 hours of treatment, participants rated their satisfaction with the treatment on a 7-step scale from extremely dissatisfied to extremely satisfied. |
Countries
United States
Participant flow
Pre-assignment details
Two hundred twenty-seven patients were screened.
Participants by arm
| Arm | Count |
|---|---|
| Flurbiprofen 8.75 mg Lozenge Participants sucked flurbiprofen 8.75mg lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days. | 102 |
| Placebo Lozenge Participants sucked vehicle placebo lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days. | 102 |
| Total | 204 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 2 | 3 |
| Overall Study | Physician Decision | 2 | 0 |
| Overall Study | Protocol Violation | 0 | 1 |
| Overall Study | Withdrawal by Subject | 5 | 3 |
Baseline characteristics
| Characteristic | Total | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|---|
| Age, Continuous | 19.8 years STANDARD_DEVIATION 1.47 | 19.8 years STANDARD_DEVIATION 1.48 | 19.8 years STANDARD_DEVIATION 1.47 |
| Difficulty Swallowing Scale (DSS) | 76.6 units on a scale STANDARD_DEVIATION 11.72 | 76.9 units on a scale STANDARD_DEVIATION 12.41 | 76.3 units on a scale STANDARD_DEVIATION 11.04 |
| Race/Ethnicity, Customized Asian | 4 participants | 3 participants | 1 participants |
| Race/Ethnicity, Customized Black or African | 7 participants | 5 participants | 2 participants |
| Race/Ethnicity, Customized Hispanic or Latino | 11 participants | 6 participants | 5 participants |
| Race/Ethnicity, Customized Multi-racial | 1 participants | 0 participants | 1 participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 1 participants | 0 participants | 1 participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 193 participants | 96 participants | 97 participants |
| Race/Ethnicity, Customized Other, not specified | 4 participants | 2 participants | 2 participants |
| Race/Ethnicity, Customized White | 187 participants | 92 participants | 95 participants |
| Sex: Female, Male Female | 117 Participants | 54 Participants | 63 Participants |
| Sex: Female, Male Male | 87 Participants | 48 Participants | 39 Participants |
| Sore Throat Pain Intensity Scale (STPIS) | 79.7 units on a scale STANDARD_DEVIATION 8.27 | 78.8 units on a scale STANDARD_DEVIATION 8.56 | 80.5 units on a scale STANDARD_DEVIATION 7.92 |
| Swollen Throat Scale (SwoTS) | 77.8 units on a scale STANDARD_DEVIATION 13.07 | 76.6 units on a scale STANDARD_DEVIATION 13.98 | 79.0 units on a scale STANDARD_DEVIATION 12.05 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 36 / 102 | 33 / 102 |
| serious Total, serious adverse events | 0 / 102 | 0 / 102 |
Outcome results
Primary
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24)
STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID24 was calculated as the sum of the time-weighted pain intensity differences from baseline until 24 hours. The full range was -114609 (complete pain relief within 2 minutes of dosing that lasts 24 hours) to 29191 (maximum pain within 2 minutes lasting 24 hours) using the mean baseline STPIS. Participants with a last recorded time point \<21 hours were considered Not Evaluable. If a participant used rescue medication, all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose.
Time frame: baseline (pre-dose), 24 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-24)
Population: Intent to treat population of participants who took the first full dose of medication. Three participants (1 Flurbiprofen, 2 Placebo) did not have sufficient 24 hour data to be included in the primary analysis of the primary endpoint (no entries after 2 hours), but did have sufficient data to be included in other efficacy analyses.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24) | -473.7 units on a scale | Standard Error 45.4428 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24) | -322.3 units on a scale | Standard Error 45.6708 |
p-value: 0.020195% CI: [-278.9, -24]ANOVA
Secondary
Change From Baseline at 24 Hours in the Tonsillo-Pharyngitis Assessment (TPA) Scores in Participants With Baseline TPA Scores >=8
Tonsillo-Pharyngitis Assessment, or TPA, is an index of seven clinical features of the pain-producing condition itself, pharyngeal inflammation. The clinical features concern temperature, oropharyngeal color, size of tonsils, number of enanthems, largest size of cervical lymph node, number of lymph nodes, and maximum tenderness of lymph nodes. Each variable was rated on a scale of 0-3, with 0 representing the normal value, and 3 representing severe inflammation. The seven values are added together to create the TPA, ranging from 0-21. Negative change values represent improvement of symptoms.
Time frame: Baseline (pre-dose), 24 hours post-dose
Population: Intent to treat population of participants whose baseline TPA was \>=8 and had an assessment at hour 24.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | Change From Baseline at 24 Hours in the Tonsillo-Pharyngitis Assessment (TPA) Scores in Participants With Baseline TPA Scores >=8 | -1.2 units on a scale | Standard Deviation 2.61 |
| Placebo Lozenge | Change From Baseline at 24 Hours in the Tonsillo-Pharyngitis Assessment (TPA) Scores in Participants With Baseline TPA Scores >=8 | -2.0 units on a scale | Standard Deviation 2.71 |
p-value: 0.0459Wilcoxon (Mann-Whitney)
Secondary
Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose
Investigators assessed the effectiveness of study medication on the patient's sore throat at 24 hours following initial dose by answering the following question: Considering the patient's response to the study medicine over the past 24 hours, how do you rate the study medicine as a treatment for sore throat? Responses were poor, fair, good, very good or excellent.
Time frame: 24 hours
Population: Intent to treat population. Three participants withdrew before the 24 hour assessment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose | Fair | 34.7 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose | Very Good | 13.9 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose | Good | 19.8 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose | Excellent | 15.8 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose | Poor | 15.8 percentage of participants |
| Placebo Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose | Excellent | 3.0 percentage of participants |
| Placebo Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose | Poor | 38.0 percentage of participants |
| Placebo Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose | Fair | 28.0 percentage of participants |
| Placebo Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose | Good | 18.0 percentage of participants |
| Placebo Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose | Very Good | 13.0 percentage of participants |
p-value: 0.0005Wilcoxon (Mann-Whitney)
Secondary
Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7)
Investigators assessed the effectiveness of study medication on the patient's sore throat at the end of the study by answering the following question: Considering the patient's response to the study medicine over the past 7 days, how do you rate the study medicine as a treatment for sore throat? Responses were poor, fair, good, very good or excellent.
Time frame: Day 7
Population: Intent to treat population of participants who had an end of study assessment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7) | Poor | 11.8 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7) | Good | 30.1 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7) | Fair | 28.0 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7) | Very Good | 17.2 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7) | Excellent | 12.9 percentage of participants |
| Placebo Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7) | Very Good | 14.7 percentage of participants |
| Placebo Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7) | Excellent | 4.2 percentage of participants |
| Placebo Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7) | Poor | 31.6 percentage of participants |
| Placebo Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7) | Fair | 34.7 percentage of participants |
| Placebo Lozenge | Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7) | Good | 14.7 percentage of participants |
p-value: 0.0002Wilcoxon (Mann-Whitney)
Secondary
Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement
As part of a protocol amendment, some participants defined a definite improvement level (DIL) relative to their actual pretreatment STPIS on the 100-mm visual analog scale. This was done after completing the 7 day trial. An alternative definition of STPIS time to onset of relief was the time from initial dose to the time the participant reaching DIL for at least 30 minutes. Data were censored if DIL was not achieved by 120 minutes following initial dose. Definite improvement must also occur prior to re-dosing or using rescue medication.
Time frame: 2 hours
Population: Intent to treat population of participants who completed the Definite Improvement Level (DIL) following study completion.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement | NA minutes |
| Placebo Lozenge | Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement | NA minutes |
p-value: 0.0273Log Rank
Secondary
Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement Duration of Relief Using Participant-Defined Definite Improvement Levels (DIL)
As part of a protocol amendment, some participants defined a definite improvement level (DIL) relative to their actual pretreatment STPIS on the 100-mm visual analog scale. This was done after completing the 7 day trial. The time of first achieving DIL for 30 minutes within 6 hours (or until rescue or re-dosing) post-dosing will be determined. And the time falling below DIL within 6 hours will be determined. Duration is then defined as the time from first DIL until falling below DIL. Duration was set to zero if the STPIS score does not reach the DIL for at least 30 minutes for STPIS during the 6 hours.
Time frame: 6 hours
Population: Intent to treat population of participants who completed the Definite Improvement Level (DIL) following study completion.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement Duration of Relief Using Participant-Defined Definite Improvement Levels (DIL) | 75.2 minutes | Standard Deviation 102.41 |
| Placebo Lozenge | Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement Duration of Relief Using Participant-Defined Definite Improvement Levels (DIL) | 29.4 minutes | Standard Deviation 65.06 |
p-value: 0.0098Wilcoxon (Mann-Whitney)
Secondary
Participant Satisfaction Scores 24 Hours After Initial Dose
After 24 hours of treatment, participants rated their satisfaction with the treatment on a 7-step scale from extremely dissatisfied to extremely satisfied.
Time frame: 24 hours
Population: Intent to treat population. Three participants withdrew before the 24 hour assessment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | Participant Satisfaction Scores 24 Hours After Initial Dose | Dissatisfied | 11.9 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Participant Satisfaction Scores 24 Hours After Initial Dose | Satisfied | 20.8 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Participant Satisfaction Scores 24 Hours After Initial Dose | Very dissatisfied | 6.9 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Participant Satisfaction Scores 24 Hours After Initial Dose | Very satisfied | 23.8 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Participant Satisfaction Scores 24 Hours After Initial Dose | Somewhat satisfied | 29.7 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Participant Satisfaction Scores 24 Hours After Initial Dose | Extremely satisfied | 2.0 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Participant Satisfaction Scores 24 Hours After Initial Dose | Extremely dissatisfied | 5.0 percentage of participants |
| Placebo Lozenge | Participant Satisfaction Scores 24 Hours After Initial Dose | Extremely satisfied | 2.0 percentage of participants |
| Placebo Lozenge | Participant Satisfaction Scores 24 Hours After Initial Dose | Extremely dissatisfied | 10.0 percentage of participants |
| Placebo Lozenge | Participant Satisfaction Scores 24 Hours After Initial Dose | Very dissatisfied | 20.0 percentage of participants |
| Placebo Lozenge | Participant Satisfaction Scores 24 Hours After Initial Dose | Dissatisfied | 14.0 percentage of participants |
| Placebo Lozenge | Participant Satisfaction Scores 24 Hours After Initial Dose | Somewhat satisfied | 28.0 percentage of participants |
| Placebo Lozenge | Participant Satisfaction Scores 24 Hours After Initial Dose | Satisfied | 17.0 percentage of participants |
| Placebo Lozenge | Participant Satisfaction Scores 24 Hours After Initial Dose | Very satisfied | 9.0 percentage of participants |
p-value: 0.0005Wilcoxon (Mann-Whitney)
Secondary
Practitioner's Assessment of Pharyngeal Inflammation (P.A.I.N.) Scores at 24 Hours After Initial Dose
P.A.I.N is a four step scale in which physicians rate the severity of pharyngeal inflammation: No inflammation, mild, moderate and severe inflammation.
Time frame: 24 hours post-dose
Population: Intent to treat population. Three participants withdrew before the 24 hour assessment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | Practitioner's Assessment of Pharyngeal Inflammation (P.A.I.N.) Scores at 24 Hours After Initial Dose | No inflammation | 0 participants |
| Flurbiprofen 8.75 mg Lozenge | Practitioner's Assessment of Pharyngeal Inflammation (P.A.I.N.) Scores at 24 Hours After Initial Dose | Mild inflammation | 48 participants |
| Flurbiprofen 8.75 mg Lozenge | Practitioner's Assessment of Pharyngeal Inflammation (P.A.I.N.) Scores at 24 Hours After Initial Dose | Moderate inflammation | 42 participants |
| Flurbiprofen 8.75 mg Lozenge | Practitioner's Assessment of Pharyngeal Inflammation (P.A.I.N.) Scores at 24 Hours After Initial Dose | Severe inflammation | 11 participants |
| Placebo Lozenge | Practitioner's Assessment of Pharyngeal Inflammation (P.A.I.N.) Scores at 24 Hours After Initial Dose | Severe inflammation | 7 participants |
| Placebo Lozenge | Practitioner's Assessment of Pharyngeal Inflammation (P.A.I.N.) Scores at 24 Hours After Initial Dose | No inflammation | 1 participants |
| Placebo Lozenge | Practitioner's Assessment of Pharyngeal Inflammation (P.A.I.N.) Scores at 24 Hours After Initial Dose | Moderate inflammation | 50 participants |
| Placebo Lozenge | Practitioner's Assessment of Pharyngeal Inflammation (P.A.I.N.) Scores at 24 Hours After Initial Dose | Mild inflammation | 42 participants |
p-value: 0.8383Wilcoxon (Mann-Whitney)
Secondary
Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose
Participants used a 6-category relief scale (no relief to complete relief) to grade the relief of his/her throat pain. The patient was instructed to swallow and: Considering how your throat felt before you took the study medicine, circle the phrase that best describes the relief of your sore throat now.
Time frame: 2 hours
Population: Intent to treat population of participants who had a 2 hour assessment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose | Slight relief | 23.5 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose | Complete relief | 0 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose | Mild relief | 23.5 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose | No relief | 18.6 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose | Moderate relief | 20.6 percentage of participants |
| Flurbiprofen 8.75 mg Lozenge | Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose | Considerable relief | 13.7 percentage of participants |
| Placebo Lozenge | Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose | Complete relief | 0 percentage of participants |
| Placebo Lozenge | Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose | Considerable relief | 4.9 percentage of participants |
| Placebo Lozenge | Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose | No relief | 45.1 percentage of participants |
| Placebo Lozenge | Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose | Slight relief | 24.5 percentage of participants |
| Placebo Lozenge | Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose | Mild relief | 11.8 percentage of participants |
| Placebo Lozenge | Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose | Moderate relief | 13.7 percentage of participants |
p-value: <0.0001Wilcoxon (Mann-Whitney)
Secondary
Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline
Participants were asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale at Baseline and until 24 hours post dose. Participants were instructed to swallow and Place a line on the scale that best characterizes how difficult it is to swallow now. A mark at 0-mm indicated no difficulty and 100-mm indicated very difficult. Data is reported as the sum of the time-weighted pain intensity differences from baseline until 24 hours post dose. The full range was -110304 (no difficulty swallowing within 10 minutes of dosing that lasts 24 hours) to 33696 (maximum difficulty swallowing within 10 minutes lasting 24 hours) using the baseline DSS value. Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation.
Time frame: baseline (pre-dose), 24 hours post-dose (every 10 minutes until hour 2, every 30 minutes until hour 6, hourly from 7-24 hours)
Population: Intent to treat population of participants who took the first full dose of medication and had DSS recorded after 21-hours.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline | -460.8 units on a scale | Standard Deviation 498.79 |
| Placebo Lozenge | Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline | -274.3 units on a scale | Standard Deviation 455.35 |
p-value: 0.007195% CI: [-313.7, -50]ANOVA
Secondary
Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline
Participants were asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale at Baseline and 2 hours post dose. Participants were instructed to swallow and Place a line on the scale that best characterizes how difficult it is to swallow now. A mark at 0-mm indicated no difficulty and 100-mm indicated very difficult. Data is reported as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dose. The full range was -9192 (no difficulty swallowing within 10 minutes of dosing that lasts 2 hours) to 2808 (maximum difficulty swallowing within 10 minutes lasting 2 hours) using the baseline DSS value. Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation.
Time frame: baseline (pre-dose), 2 hours post-dose (every 10 minutes until hour 2)
Population: Intent to treat population of participants who took the first full dose of medication.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline | -39.1 units on a scale | Standard Deviation 38.64 |
| Placebo Lozenge | Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline | -16.6 units on a scale | Standard Deviation 29.34 |
p-value: <0.000195% CI: [-31.7, -12.9]ANOVA
Secondary
Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline
The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale at Baseline and specified timeframes until 24 hours. The patient was instructed to swallow and Place a line on the scale that best characterizes how swollen your throat feels now. A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 24 hours was -112032 (throat did not feel swollen at all within 1 hour of dosing and lasted 24 hours) to 31968 (maximum swollen throat reported within 1 hour and lasting 24 hours) using the mean baseline SwoTS.
Time frame: baseline (pre-dose), 24 hours post-dose (1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, 2 hours, 2½ hours, 3 hours, 3½ hours, 4 hours, 4½ hours, 5 hours, 5½ hours, and 6 hours after the first dose, hourly from 7-24 hours)
Population: Intent to treat population of participants who took the first full dose of medication, and had SwoTS recorded after 21 hours. Four participants (1 Flurbiprofen, 3 Vehicle) did not have SwoTS recorded after 21 hours and were not included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline | -472.2 units on a scale | Standard Deviation 521.89 |
| Placebo Lozenge | Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline | -355.2 units on a scale | Standard Deviation 432.04 |
p-value: 0.039395% CI: [-268.5, -6.8]ANOVA
Secondary
Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline
The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale at Baseline and at 1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, and 2 hours. The patient was instructed to swallow and Place a line on the scale that best characterizes how swollen your throat feels now. A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 2 hours was -9336 (throat did not feel swollen at all within 1 hour of dosing and lasted 2 hours) to 2664 (maximum swollen throat reported within 1 hour and lasting 2 hours) using the mean baseline SwoTS.
Time frame: baseline (pre-dose), 2 hours post-dose (at 1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, and 2 hours)
Population: Intent to treat population of participants who took the first full dose of medication.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline | -39.9 units on a scale | Standard Deviation 39.63 |
| Placebo Lozenge | Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline | -20.1 units on a scale | Standard Deviation 27.28 |
p-value: <0.000195% CI: [-30.2, -11.2]ANOVA
Secondary
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe
STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. For the subgroup of patients with moderate/severe pharyngeal inflammation at baseline, SPID24 was calculated as the sum of the time weighted pain intensity differences from baseline until 24 hours. Taking inclusion criteria into account, the full range was -116196 (no pain at any post-dose time (0) - average baseline) to 27804 (maximum possible pain (100) - average baseline). Participants with their last recorded time point \<21 hours were considered Not Evaluable. If a participant used rescue medication (acetaminophen 650mg was allowed as needed), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation.
Time frame: baseline (pre-dose), 24 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-24)
Population: Intent to treat population of participants who took the first full dose of medication and had moderate or severe pharyngeal inflammation at baseline.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe | -451.4 units on a scale | Standard Deviation 491.05 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe | -283.4 units on a scale | Standard Deviation 378.06 |
p-value: 0.043595% CI: [-307.9, -4.6]ANOVA
Secondary
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05
Data reported in summary form in Primary Outcome #1 are reported here at each post-dose timepoint until the comparison resulted in a P-value \<=0.05 between the two treatment arms. STPIS was used to measure sore throat pain intensity using a 100-mm visual analog scale completed by participants that measures pain on swallowing (odynophagia). A mark at 0-mm indicates no pain and 100-mm indicates severe pain. The full range of the scale varies by timepoint due to the time weighting sum of SPID. The full scale at 40 minutes post dose was -3188 (complete pain relief within 2 minutes of dosing that lasts 40 minutes) to 812 (maximum pain within 2 minutes lasting 40 minutes) using the mean baseline STPIS. If a participant used rescue medication (acetaminophen 650mg was allowed as needed), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (rec
Time frame: baseline (pre-dose), up to 23 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-23)
Population: Intent to treat population of participants who took the first full dose of medication.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 2 | -0.1 units on a scale | Standard Deviation 0.26 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 4 | -0.3 units on a scale | Standard Deviation 0.62 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 6 | -0.6 units on a scale | Standard Deviation 1.05 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 8 | -0.9 units on a scale | Standard Deviation 1.56 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 10 | -1.4 units on a scale | Standard Deviation 2.1 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 12 | -1.9 units on a scale | Standard Deviation 2.68 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 14 | -2.4 units on a scale | Standard Deviation 3.3 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 16 | -3.0 units on a scale | Standard Deviation 3.94 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 18 | -3.5 units on a scale | Standard Deviation 4.56 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 20 | -4.1 units on a scale | Standard Deviation 5.19 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 22 | -4.7 units on a scale | Standard Deviation 5.83 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 24 | -5.2 units on a scale | Standard Deviation 6.46 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 26 | -5.9 units on a scale | Standard Deviation 7.12 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 28 | -6.5 units on a scale | Standard Deviation 7.76 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 30 | -7.2 units on a scale | Standard Deviation 8.41 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 32 | -7.9 units on a scale | Standard Deviation 9.09 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 34 | -8.6 units on a scale | Standard Deviation 9.77 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 36 | -9.3 units on a scale | Standard Deviation 10.45 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 38 | -10.1 units on a scale | Standard Deviation 11.14 |
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 40 | -10.8 units on a scale | Standard Deviation 11.8 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 36 | -7.1 units on a scale | Standard Deviation 8.37 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 2 | -0.2 units on a scale | Standard Deviation 0.33 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 22 | -4.1 units on a scale | Standard Deviation 4.95 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 4 | -0.4 units on a scale | Standard Deviation 0.69 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 32 | -6.2 units on a scale | Standard Deviation 7.36 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 6 | -0.8 units on a scale | Standard Deviation 1.14 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 24 | -4.5 units on a scale | Standard Deviation 5.43 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 8 | -1.2 units on a scale | Standard Deviation 1.6 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 40 | -7.9 units on a scale | Standard Deviation 9.38 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 10 | -1.6 units on a scale | Standard Deviation 2.11 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 26 | -4.9 units on a scale | Standard Deviation 5.69 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 12 | -2.1 units on a scale | Standard Deviation 2.59 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 34 | -6.6 units on a scale | Standard Deviation 7.87 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 14 | -2.5 units on a scale | Standard Deviation 3.08 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 28 | -5.3 units on a scale | Standard Deviation 6.37 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 16 | -2.9 units on a scale | Standard Deviation 3.56 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 38 | -7.5 units on a scale | Standard Deviation 8.87 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 18 | -3.3 units on a scale | Standard Deviation 4.01 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 30 | -5.8 units on a scale | Standard Deviation 6.87 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05 | Minutes post dose: 20 | -3.7 units on a scale | Standard Deviation 4.47 |
Comparison: Minutes post dose: 2p-value: 0.144895% CI: [0, 0.1]ANOVA
Comparison: Minutes post dose: 4p-value: 0.153895% CI: [0, 0.3]ANOVA
Comparison: Minutes post dose: 6p-value: 0.140795% CI: [-0.1, 0.5]ANOVA
Comparison: Minutes post dose: 8p-value: 0.290695% CI: [-0.2, 0.7]ANOVA
Comparison: Minutes post dose: 10p-value: 0.475895% CI: [-0.4, 0.8]ANOVA
Comparison: Minutes post dose: 12p-value: 0.697595% CI: [-0.6, 0.9]ANOVA
Comparison: Minutes post dose: 14p-value: 0.93795% CI: [-0.8, 0.9]ANOVA
Comparison: Minutes post dose: 16p-value: 0.849395% CI: [-1.1, 0.9]ANOVA
Comparison: Minutes post dose: 18p-value: 0.673295% CI: [-1.4, 0.9]ANOVA
Comparison: Minutes post dose: 20p-value: 0.541495% CI: [-1.8, 0.9]ANOVA
Comparison: Minutes post dose: 22p-value: 0.431395% CI: [-2.1, 0.9]ANOVA
Comparison: Minutes post dose: 24p-value: 0.350195% CI: [-2.4, 0.9]ANOVA
Comparison: Minutes post dose: 26p-value: 0.267995% CI: [-2.8, 0.8]ANOVA
Comparison: Minutes post dose: 28p-value: 0.213795% CI: [-3.2, 0.7]ANOVA
Comparison: Minutes post dose: 30p-value: 0.171595% CI: [-3.6, 0.6]ANOVA
Comparison: Minutes post dose: 32p-value: 0.13495% CI: [-4.1, 0.5]ANOVA
Comparison: Minutes post dose: 34p-value: 0.10395% CI: [-4.5, 0.4]ANOVA
Comparison: Minutes post dose: 36p-value: 0.078895% CI: [-5, 0.3]ANOVA
Comparison: Minutes post dose: 38p-value: 0.06295% CI: [-5.5, 0.1]ANOVA
Comparison: Minutes post dose: 40p-value: 0.047695% CI: [-6, 0]ANOVA
Secondary
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2)
STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID2 was calculated as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dosing. The full range was -9405 (complete pain relief within 2 minutes of dosing that lasts 2 hours) to 2395 (maximum pain within 2 minutes lasting 2 hours) using the mean baseline STPIS. If a participant used rescue medication (acetaminophen 650mg was allowed as needed post dose), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (recorded or derived due to rescue) were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose.
Time frame: baseline (pre-dose), 2 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2)
Population: Intent to treat population of participants who took the first full dose of medication.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2) | -43.4 units on a scale | Standard Deviation 39.2 |
| Placebo Lozenge | Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2) | -23.5 units on a scale | Standard Deviation 29.52 |
p-value: <0.000195% CI: [-29.2, -9.9]ANOVA